PathAI And MedStar Team Up To Bring AI-Powered Digital Pathology Across Multi-Site Network

PathAI, a leading developer of AI-powered pathology technologies, has entered into a multi-year strategic collaboration with MedStar Health, a major health system headquartered in Columbia, Maryland. Through this partnership, MedStar Health will implement PathAI’s AISight Dx1 Digital Pathology Platform, along with several advanced AI algorithms, across its multi-site laboratory network.

AISight Dx is a cloud-native digital pathology image management system designed to support a wide range of laboratory needs, including workflow management, clinical operations, and research activities. The platform enables large-scale slide storage, fast and consistent image viewing, and improved collaboration between teams. It also integrates seamlessly with PathAI’s suite of AI tools, helping laboratories enhance efficiency, accuracy, and speed in their diagnostic processes. As part of the deployment, MedStar Health will also use AI algorithms such as ArtifactDetect and TumorDetect2 to further enhance pathology workflows for the more than 40 pathologists working within the system.

Moira Larsen, MD, Physician Executive Director of MedStar Medical Group Pathology, stated that digital pathology plays a vital role in MedStar Health’s efforts to expand high-quality care across its growing network and outreach programs. She explained that introducing AISight Dx and PathAI’s AI applications will modernize the organization’s pathology infrastructure, improve system-wide connectivity, and help bring innovative diagnostic tools into everyday patient care. According to Larsen, this collaboration supports MedStar’s ongoing commitment to adopting advanced digital and AI technologies while maintaining a strong focus on delivering excellent clinical outcomes for the communities it serves.

The system-wide rollout of AISight Dx builds on MedStar Health’s previous participation in PathAI’s Early Access Program and earlier research partnerships, including its independent validation of PathAI’s AIM-HER2 Breast algorithm. The new collaboration also strengthens MedStar Health’s involvement in PathAI’s Precision Pathology Network, creating opportunities for joint research projects, the development of real-world multimodal datasets, support for clinical trials and biopharmaceutical initiatives, and co-development of future AI-enhanced diagnostic tools.

Nick Brown, Chief Growth Officer at PathAI, noted that digital pathology and artificial intelligence are transforming how health systems generate insights and expand their clinical impact. He said the partnership with MedStar Health will help establish a modern digital infrastructure that supports ongoing innovation and positions MedStar for long-term growth in its pathology services.